Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol, statins and tau.

T G Ohm1, V Meske

  • 1Institute of Integrative Neuroanatomy, Department of Clinical Cell- and Neurobiology, Charité-Universitätsmedizin Berlin, Germany. thomas_georg.ohm@charite.de

Acta Neurologica Scandinavica. Supplementum
|July 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta/A4-Amyloid increases nerve growth factor production in rat primary hippocampal astrocyte cultures.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2007
Same author

Pathological cholesterol metabolism fails to modify electrophysiological properties of afflicted neurones in Niemann-Pick disease type C.

Neuroscience·2005
Same author

Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype.

Neuroscience·2003
Same author

Cholesterol and tau protein--findings in Alzheimer's and Niemann Pick C's disease.

Pharmacopsychiatry·2003
Same author

Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.

The European journal of neuroscience·2003
Same author

Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease.

Neuroscience·2002
Same journal

Sleep quality and arousal in migraine and tension-type headache: the headache-sleep study.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Diffusion-weighted lesions in acute ischaemic stroke patients with migraine.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Mild stroke: safety and outcome in patients receiving thrombolysis.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Advances in genetic diagnosis of neurological disorders.

Acta neurologica Scandinavica. Supplementum·2014
See all related articles

Cholesterol metabolism influences Alzheimer's disease (AD) progression. Statins may slow AD, and cholesterol changes impact tau pathology, independent of amyloid plaques.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Alzheimer's disease (AD) risk factors are linked to cholesterol metabolism.
  • Statins, cholesterol biosynthesis inhibitors, may reduce AD progression.
  • Niemann-Pick type C disease exhibits AD-like tau pathology without amyloid plaques.

Purpose of the Study:

  • Investigate the mechanisms linking cholesterol metabolism to AD.
  • Explore how cholesterol levels influence tau pathology.
  • Determine if Abeta-protein aggregates are necessary for cholesterol-induced tau changes.

Main Methods:

  • Review of existing literature on cholesterol metabolism and AD.
  • Analysis of data from hereditary cholesterol-storage disorders (e.g., Niemann-Pick C).

Related Experiment Videos

  • Examination of experimental data on cholesterol manipulation and tau phosphorylation.

    • Main Results:

    • Cholesterol metabolism disturbances can induce tau pathology independently of amyloid plaques.
    • Experimental data suggest cholesterol level manipulation alters tau phosphorylation.
    • Observed changes in tau phosphorylation vary based on the method of cholesterol manipulation.

    Conclusions:

    • Cholesterol metabolism plays a significant role in Alzheimer's disease pathogenesis.
    • Tau pathology can be influenced by cholesterol dysregulation without amyloid involvement.
    • Further research is needed to elucidate the precise mechanisms of statins and cholesterol in AD.